Abstract
Although it is increasingly being recognized that drug-target interaction networks can be powerful tools for the interrogation of systems biology and the rational design of multitargeted drugs, there is no generalized, statistically validated approach to harmonizing sequence-dependent and pharmacology-dependent networks. Here we demonstrate the creation of a comprehensive kinome interaction network based not only on sequence comparisons but also on multiple pharmacology parameters derived from activity profiling data. The framework described for statistical interpretation of these network connections also enables rigorous investigation of chemotype-specific interaction networks, which is critical for multitargeted drug design.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Deep learning in drug discovery: an integrative review and future challenges
Artificial Intelligence Review Open Access 17 November 2022
-
Identification of pan-kinase-family inhibitors using graph convolutional networks to reveal family-sensitive pre-moieties
BMC Bioinformatics Open Access 22 June 2022
-
Exploring kinase family inhibitors and their moiety preferences using deep SHapley additive exPlanations
BMC Bioinformatics Open Access 20 June 2022
Access options
Subscribe to Journal
Get full journal access for 1 year
$119.00
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.


References
Roth, B.L., Sheffler, D.J. & Kroeze, W.K. Nat. Rev. Drug Discov. 3, 353–359 (2004).
Frantz, S. Nature 437, 942–943 (2005).
Morphy, R. J. Med. Chem. 53, 1413–1437 (2010).
Mestres, J., Gregori-Puigjane, E., Valverde, S. & Sole, R.V. Mol. Biosyst. 5, 1051–1057 (2009).
Paolini, G.V., Shapland, R.H., van Hoorn, W.P., Mason, J.S. & Hopkins, A.L. Nat. Biotechnol. 24, 805–815 (2006).
Keiser, M.J. et al. Nat. Biotechnol. 25, 197–206 (2007).
Keiser, M.J. et al. Nature 462, 175–181 (2009).
Oprea, T.I., Tropsha, A., Faulon, J.L. & Rintoul, M.D. Nat. Chem. Biol. 3, 447–450 (2007).
Vogt, I. & Mestres, J. Mol. Inf. 29, 10–14 (2010).
Metz, J.T. & Hajduk, P.J. Curr. Opin. Chem. Biol. 14, 498–504 (2010).
Vieth, M. et al. Biochim. Biophys. Acta 1697, 243–257 (2004).
Vieth, M., Sutherland, J.J., Robertson, D.H. & Campbell, R.M. Drug Discov. Today 10, 839–846 (2005).
Bamborough, P., Drewry, D., Harper, G., Smith, G.K. & Schneider, K. J. Med. Chem. 51, 7898–7914 (2008).
Mestres, J., Gregori-Puigjane, E., Valverde, S. & Sole, R.V. Nat. Biotechnol. 26, 983–984 (2008).
Godden, J.W. & Bajorath, J. J. Mol. Graph. Model. 18, 73–76 (2000).
Godden, J.W. & Bajorath, J. QSAR Comb. Sci. 22, 487–497 (2003).
Author information
Authors and Affiliations
Contributions
J.T.M. performed all of the statistical analyses and created the network visualizations; E.F.J. designed the initial kinome screening panel and supervised the enzymology; N.B.S., P.J.M. and L.K. performed all kinase assays; P.J.H. supervised the research and wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
All authors are currently employed by and obtain their salary from Abbott Laboratories.
Supplementary information
Supplementary Text and Figures
Supplementary Methods, Supplementary Figures 1–6 and Supplementary Tables 1 & 2 descriptions (PDF 1153 kb)
Supplementary Table 1
Kinome pKi data with clusters (xls) (XLS 3912 kb)
Supplementary Table 2
Kinome pharmacology interactions (csv) (CSV 3218 kb)
Supplementary Dataset
Kinome pharmacology analysis, .txt file for Pipeline Pilot (XML 557 kb)
Rights and permissions
About this article
Cite this article
Metz, J., Johnson, E., Soni, N. et al. Navigating the kinome. Nat Chem Biol 7, 200–202 (2011). https://doi.org/10.1038/nchembio.530
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.530
This article is cited by
-
Identification of pan-kinase-family inhibitors using graph convolutional networks to reveal family-sensitive pre-moieties
BMC Bioinformatics (2022)
-
Exploring kinase family inhibitors and their moiety preferences using deep SHapley additive exPlanations
BMC Bioinformatics (2022)
-
Explainable deep drug–target representations for binding affinity prediction
BMC Bioinformatics (2022)
-
Discovery of moiety preference by Shapley value in protein kinase family using random forest models
BMC Bioinformatics (2022)
-
HIDTI: integration of heterogeneous information to predict drug-target interactions
Scientific Reports (2022)